Overview

Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain

Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
A phase 2 randomized clinical trial to evaluate efficacy and safety of SPARC1401 at three dose levels in patients with acute low back pain
Phase:
Phase 2
Details
Lead Sponsor:
Sun Pharma Advanced Research Company Limited
Treatments:
Tizanidine